Results 211 to 220 of about 1,414,906 (307)

Depletion of the RNA‐Editing Enzyme ADAR1 Invigorates the Antitumor Immunity of NK Cells

open access: yesAdvanced Science, EarlyView.
ADAR1 is upregulated in NK cells from melanoma patients, impairing their function. Its loss enhances NK cell tumor infiltration and cytotoxicity in vitro and in vivo. Mechanistically, ADAR1 deficiency destabilizes CD38 mRNA to reduce its expression, thereby increasing NK cell mobility and killing, which nominates it as a therapeutic target for NK cell ...
Shuhan Chen   +11 more
wiley   +1 more source

Gemella morbillorum Promotes Colorectal Carcinogenesis: LPBDCP‐Mediated Invasion Activates Ras Signaling and Destabilizes p53

open access: yesAdvanced Science, EarlyView.
ABSTRACT Gut microbiota dysbiosis promotes colorectal cancer (CRC) tumorigenesis. A global fecal metagenomic analysis identified Gemella morbillorum as a key contributor to the CRC‐associated microbiota. Fluorescence in situ hybridization revealed that Gemella morbillorum is enriched in CRC tumor tissues compared to adjacent normal tissues.
Zhen Wang   +8 more
wiley   +1 more source

Hierarchical Targeting of TREM2+ Myeloid Cells via Acid‐Triggered OMVs Reprogram Immunosuppression and Suppress Osteolysis in Bone‐Metastatic TNBC

open access: yesAdvanced Science, EarlyView.
This study developed a hierarchical targeting nanoplatform, siTREM2@ETP‐PEOz‐OMVs, against triple‐negative breast cancer (TNBC) bone metastasis. It precisely delivers therapeutic siTREM2 to monocytes/macrophages within the metastatic niche. This intervention dually regulates cell fate: reprogramming immunosuppressive macrophages and inhibiting ...
Fanglu Chen   +12 more
wiley   +1 more source

Hypofractionated Radiotherapy Induces ISG15+MHC‐I+ Neutrophils to Augment Anti‐Tumor Immunity and Prime Immune Checkpoint Blockade Responses in Rectal Cancer

open access: yesAdvanced Science, EarlyView.
ABSTRACT Our previous clinical trials had demonstrated that neoadjuvant hypofractionated radiotherapy (HFRT) combined with immunotherapy yields promising clinical outcomes in locally advanced rectal cancer (LARC). However, this combined modality benefits only a subset of patients, highlighting the need to uncover the mechanisms underlying how ...
Lichao Liu   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy